Briefing
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-up of the MURANO Phase III Study
Post-treatment MRD analysis of MURANO: fixed-duration venetoclax-rituximab produced high rates of undetectable MRD that were associated with longer survival. Level 2 (MRD analysis of an RCT).
- Design: paper
- Assay: Undetectable MRD after fixed-duration Ven-R